ALLAN L. METZGER, M.D.; ANTHONY BOHAN, M.D.; LEONARD S. GOLDBERG, M.D., F.A.C.P.; RODNEY BLUESTONE, M.B., F.A.C.P.; CARL M. PEARSON, M.D., F.A.C.P.
Twenty-two patients with polymyositis and dermatomyositis were treated with combined prednisone and intravenous methotrexate when moderate to high-dose cortisone alone was ineffective in controlling disease activity. Definite clinical improvement was noted in 17 or 77% of the patients. Those patients responding to therapy normalized their muscle enzymes (creatine Phosphokinase, CPK) after a mean period of 10 weeks; moreover, the onset of muscle strength improvement was noted at an average of 13 weeks. A "steroid-sparing" effect was noted in that the prednisone dose has been decreased from 47 mg/day (premethotrexate) to 12 mg/day at 15 months follow-up. Toxicity to methotrexate was minor and reversible. After an average treatment period of more than 1 year, and a total average dose of over 1 g methotrexate, clinical and laboratory hepatotoxicity was not found. Intravenous methotrexate is an important treatment for polymyositis and dermatomyositis.
METZGER AL, BOHAN A, GOLDBERG LS, BLUESTONE R, PEARSON CM. Polymyositis and Dermatomyositis: Combined Methotrexate and Corticosteroid Therapy. Ann Intern Med. ;81:182–189. doi: 10.7326/0003-4819-81-2-182
Download citation file:
Published: Ann Intern Med. 1974;81(2):182-189.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use